<DOC>
	<DOCNO>NCT01542021</DOCNO>
	<brief_summary>Degarelix approve drug use treat prostate cancer lower testosterone level body . Degarelix commonly give radiation prostate cancer , less frequently surgery since proven benefit approach . The investigator expect patient benefit directly treatment degarelix since prostate remove shortly drug give . Instead , investigator hope learn degarelix treatment lower testosterone effect prostate cancer cell use information develop good treatment future .</brief_summary>
	<brief_title>Androgen Deprivation Therapy Prior Prostatectomy Patients With Intermediate High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Histologic confirmation prostatic adenocarcinoma MSKCC inclusive following : 3 positive biopsy core equivalent tumor specimen confirm pathologist At least 2 core contain ≥3 mm tissue carcinoma equivalent tumor specimen confirm pathologist A primary tumor Gleason score ≥ 7 Adequate primary biopsy tissue equivalent tumor specimen confirm pathologist available protocol require analysis ( i.e . bladder TURP specimen ) Planning radical prostatectomy ( RP ) MSKCC Candidates may history deep vein thrombosis , pulmonary embolism , and/or cerebrovascular accident , require concomitant systemic anticoagulation , otherwise deem suitable RP Karnofsky performance status &gt; 70 % ( Appendix A ) Sexually active fertile subject , partner , must agree use medically accept method contraception ( eg , barrier method , include male condom , female condom , diaphragm spermicidal gel ) course study 3 month dose study drug ( ) Cohorts 1 , 2 4 , 3 month surgery Cohort 3 For cohort 1,2 4 : , noncastrate testosterone level ( &gt; 100 ng/dL ) For cohort 3 : , 16 month androgen deprivation therapy ( gonadotropin hormone release analog without antiandrogen ) prior prostatectomy castrate testosterone level &lt; 50 ng/dL within 1 month prior prostatectomy . Histologic variant primary tumor ( histologic variant adenocarcinoma ) Current prior chemotherapy The use 5alphareductase inhibitor dutasteride must discontinue within 4 week degarelix injection Cohort 1 , 2 4 , within 4 week surgery Cohort 3 . Saw palmetto administer intent treat patient 's malignancy within 1 week degarelix injection Cohorts 1 , 2 4 , within 1 week surgery Cohort 3 Current prior radiation therapy prostate Active infection intercurrent illness Concomitant therapy experimental drug For cohort 1 , 2 4 : , current prior hormonal therapy ( e.g. , gonadotropin hormone release analog , megestrol acetate , antiandrogens ) exclusionary</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>prostate</keyword>
	<keyword>Degarelix</keyword>
	<keyword>injection</keyword>
	<keyword>radical prostatectomy</keyword>
	<keyword>11-182</keyword>
</DOC>